RPE65 rs61754026: Understanding This Retinal Health Variant
The rs61754026 variant is a specific genetic change in the RPE65 gene that results in an amino acid substitution known as p.Arg91Trp. This variant is recognized in clinical research as a loss-of-function mutation associated with autosomal recessive inherited retinal diseases, including Leber congenital amaurosis.
What each genotype means
Typical vision risk profile
You carry two reference copies of the RPE65 gene at this position. This genotype is not associated with RPE65-related retinal dystrophies such as Leber congenital amaurosis. Your visual function risk related to this specific locus is typical of the general population.
Carried by more than 99.9% of individuals across all major global ancestries.
RPE65 carrier
You carry one copy of the pathogenic p.Arg91Trp missense variant in the RPE65 gene. Because RPE65-related Leber congenital amaurosis and early-onset retinal dystrophy are autosomal recessive conditions, single-copy carriers typically do not experience vision loss. There is a possibility of passing this variant to biological offspring, which is primarily relevant if a partner is also a carrier.
Carried by roughly 1 in 6,000 individuals globally, with slightly higher carrier frequencies observed in populations of Middle Eastern descent.
Increased retinal dystrophy risk
You carry two copies of the pathogenic p.Arg91Trp variant in the RPE65 gene. Biallelic loss-of-function variants in RPE65 are strongly associated with autosomal recessive Leber congenital amaurosis type 2 and early-onset severe retinal dystrophy, which cause profound childhood visual impairment. Genetic counseling and comprehensive ophthalmological evaluation are standard for individuals with biallelic variants.
Extremely rare in the general population, occurring in fewer than 1 in 100,000,000 individuals globally, but enriched in communities with founder effects or consanguinity.
What is the rs61754026 Variant?
The rs61754026 variant is a single nucleotide polymorphism (SNP) located within the RPE65 gene. In genetic terms, this variant represents a missense mutation, meaning that a single change in the DNA sequence leads to the substitution of one amino acid for another in the resulting protein—specifically, arginine is replaced by tryptophan at position 91 (p.Arg91Trp). Because this change occurs in a critical region of the protein, it is often categorized as a loss-of-function variant. This means the protein may not perform its intended biological role effectively. Geneticists study this variant because it is one of several known mutations in the RPE65 gene that can disrupt normal visual cycle processes, which are essential for maintaining the health and function of the light-sensing cells in the retina.
The Role of the RPE65 Gene
The RPE65 gene provides instructions for making a protein called retinoid isomerohydrolase, which is primarily found in the retinal pigment epithelium (RPE). The RPE is a layer of cells that supports the photoreceptor cells in the retina, which are responsible for detecting light. The RPE65 protein plays a vital role in the visual cycle, a complex biochemical process that regenerates the light-sensitive pigment (rhodopsin) required for vision. Without functional RPE65 protein, the retina cannot effectively recycle these pigments, leading to a buildup of toxic byproducts and the eventual death of photoreceptor cells. This dysfunction is the underlying cause of several inherited retinal diseases, characterized by progressive vision loss that often begins in early childhood.
Research and Clinical Associations
Research has established a strong link between biallelic mutations in RPE65—meaning a person inherits a pathogenic variant from both parents—and a spectrum of retinal conditions. These include Leber congenital amaurosis (LCA), early-onset severe retinal dystrophy (EOSRD), and juvenile retinitis pigmentosa. The rs61754026 variant (p.Arg91Trp) is considered a well-characterized pathogenic allele in this context. Clinical studies have observed that individuals carrying this variant, particularly when paired with another pathogenic RPE65 mutation, may experience significant visual impairment from infancy or early childhood. While the severity can vary, the evidence consistently points to this variant as a contributor to retinal degeneration. It is important to note that genetic testing and clinical evaluation by an ophthalmologist are necessary to interpret the significance of these findings in any individual, as the presence of a single variant does not necessarily confirm a diagnosis.
What You Can Do With This Information
If you have received information about your status regarding the rs61754026 variant, it is important to approach it with perspective. This variant is associated with rare, recessive conditions, meaning that carrying one copy typically does not result in the disease. If you are concerned about your vision or your family history of retinal disease, the most appropriate step is to consult with a medical geneticist or a specialized ophthalmologist. They can provide context based on your full genetic profile and clinical symptoms. Never use genetic data to self-diagnose or make medical decisions without professional guidance. If you are currently participating in clinical trials or receiving treatment for a retinal condition, always discuss your genetic results with your healthcare team, as they can help determine if specific therapies, such as gene-replacement strategies, are relevant to your specific genetic makeup.
How common is this variant?
The rs61754026 variant is rare, with a reported allele frequency in the gnomAD database of approximately 0.00008. It has been noted to have higher frequencies in specific populations, such as Saudi Arabic populations, potentially due to founder effects.
Frequently asked questions
Is rs61754026 a cause of blindness?
The rs61754026 variant is a known pathogenic mutation in the RPE65 gene. When inherited in a biallelic manner (two copies), it is associated with severe, early-onset retinal degeneration that can lead to significant vision loss or childhood blindness.
What does it mean to be a carrier of an RPE65 mutation?
Being a carrier means you have one copy of a pathogenic RPE65 variant and one normal copy. Carriers typically do not experience the symptoms of the associated retinal diseases, as the condition is inherited in an autosomal recessive pattern.
Can I be tested for this variant?
Yes, this variant can be identified through clinical genetic testing, often as part of a multigene panel for inherited retinal diseases. You should discuss the necessity and implications of such testing with a genetic counselor or ophthalmologist.
Are there treatments for RPE65-related conditions?
Yes, there are FDA-approved gene therapies available for individuals with confirmed biallelic RPE65-related retinal dystrophy. Eligibility depends on specific clinical criteria and genetic confirmation, which should be discussed with a retinal specialist.
Sources & further reading
Educational information only, last refreshed 10/17/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs61754026?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29